Cancer Genetics, Inc. Announces Pricing of Public Offering of 2,858,000 Shares of Common Stock

RUTHERFORD, N.J., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its underwritten public offering of 2,858,000 shares of its common stock at a price to the public of $14.00 per share. The gross proceeds to Cancer Genetics from the public offering are expected to be $40 million, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.

Help employers find you! Check out all the jobs and post your resume.